

03 Oct 2021 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: the prospects for Merck's Acceleron acquisition; the pandemic and biotech capital in-flow; an interview with Menarini's CEO; upcoming endocrine and metabolic product disorders; and an interview with Novartis Pharma's president.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 1 October 2021, including: the prospects for [*Merck & Co., Inc.*'s *Acceleron Pharma, Inc.*](#) acquisition; the pandemic and biotech capital in-flow; an interview with [*Menarini Group*](#)'s CEO; upcoming endocrine and metabolic product disorders; and an interview with [*Novartis AG*](#)'s pharma president.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [*Apple Podcasts*](#), [*Google Podcasts*](#), [*SoundCloud*](#), [*TuneIn*](#) and [*Spotify Podcasts*](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

The links to the websites for the inaugural Informa Pharma Intelligence Awards Japan are [*here \(English\)*](#) and [*here \(Japanese\)*](#).

Stories mentioned in this episode:

(Also see "[*Merck's \\$11.5bn Acceleron Buy Partially Fills Future Keytruda Revenue Gap*](#)" - Scrip, 30 Sep, 2021.)

(Also see "[*How The Pandemic Changed Deal-Making Between Biotechs And Big Pharma*](#)" - Scrip, 23 Sep, 2021.)

(Also see "[*Driving Menarini's Future With Decisive Steps*](#)" - Scrip, 27 Sep, 2021.)

(Also see "[*Nine Endocrine And Metabolic Disease Drug Launches To Look Out For In 2022*](#)" - Scrip, 28 Sep, 2021.)

(Also see "[*Drug Price Reform Concerns Novartis Pharma President Tschudin*](#)" - Scrip, 23 Sep, 2021.)
[Click here to explore this interactive content online](#) 